Delving into the Latest Updates on ADV-209 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

σ1 receptor x σ2 receptor

Action

antagonists, agonists

Mechanism

σ1 receptor antagonists(Sigma opioid receptor antagonists), σ2 receptor agonists(Sigma-2 receptor agonists)

Therapeutic Areas

NeoplasmsImmune System DiseasesNervous System Diseases+ [1]

Active Indication

Autoimmune DiseasesNeoplasmsPain

Inactive Indication-

Originator Organization

Advantx Pharmaceuticals

Active Organization

Advantx PharmaceuticalsNEMA Research, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Sigma receptors are protein chaperones with the unexpected characteristic of being activated by ligand binding. As such, they represent intriguing new targets for potential drug development. As a protein chaperone, these "receptors" escort proteins from the endoplasmic reticulum to their destinations and act to correct misfolded proteins. The two subtypes of sigma receptors, named σ1 and σ2, are markedly distinct from each other. Agonists and antagonists at these receptors show promise as new drug targets, addressing a range of diseases including neurodegenerative disorders, cancer, and cardiac disorders, and may also be analgesic agents and rehabilitation drugs for opioid use disorder. As an analgesic, sigma receptors seem to be more effective in treating neuropathic than nociceptive pain. New bifunctional compounds are being developed with opioids, because agents targeting sigma receptors may have an opioid-sparing effect. The pipeline of agents based on the sigma receptors is long and may treat things from Fragile X syndrome to Parkinson's disease to Huntington's disease to cancer. A novel agent ADV502 acts as a high-affinity σ1 antagonist and partial agonist at the µ-opioid receptor and may be an important agent both for the treatment of neuropathic cancer pain and for rehabilitation of opioid use disorder. Since there has been little recent innovation in pain medicine regarding new compounds and drug targets, drugs that affect the sigma receptor system seem promising and encouraging.

100 Deals associated with ADV-209

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Autoimmune Diseases	Preclinical	United States	NEMA Research, Inc.	28 Jul 2023
Autoimmune Diseases	Preclinical	United States	Advantx Pharmaceuticals	28 Jul 2023
Neoplasms	Preclinical	United States	NEMA Research, Inc.	28 Jul 2023
Neoplasms	Preclinical	United States	Advantx Pharmaceuticals	28 Jul 2023
Pain	Preclinical	United States	Advantx Pharmaceuticals	28 Jul 2023
Pain	Preclinical	United States	NEMA Research, Inc.	28 Jul 2023